Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

IPRATROPIUM BROMIDE

All products: Limited Use (codes 03)

PMS-Ipratropium · DIN 02239627 · 0.03% · Nasal Spray

Limited Use — Reason for Use code 03 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 03 required
Write on scriptLU code 03 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 03
Reason for Use code 03 For the treatment of non-allergic vasomotor rhinitis Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
PMS-Ipratropium · DIN 02239627 Manufacturer: Pharmascience Inc.; listing date 2000-07-17 Health Canada: Marketed since 1999-04-15 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 21 MCG/ACT · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Ipratropium: Formulary list price $0.9127/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9127 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63098 · Verify on the e-Formulary ↗ (DIN 02239627)

Source record
DIN 02239627: PMS-Ipratropium Raw flags: sec12=Y, sec3=Y Item: 523600082; group id 626; item number 1595; lccId 00088; manufacturer id PMS Source form: Nasal Spray; strength: 0.03% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.9127; ministry $0.9127 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239627 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63098
Interchangeable products
Atrovent · DIN 02163705 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

SODIUM CROMOGLYCATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 2% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AA-IPRAVENT (ipratropium bromide inhalation solution) is indicated for: • the treatment of bronchospasm associated with acute exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. • the treatment of bronchospasm associated with acute severe exacerbations of bronchial asthma when used in conjunction with a beta2 adrenergic agonist such as salbutamol. AA-IPRAVENT inhalation solution must be administered by means of nebulizer using gas flow (oxygen or compressed air). 1.1 Pediatrics Pediatrics (<5 years of age): Based on the data reviewed by Health Canada, the efficacy and safety of AA-IPRAVENT in children younger than 5 years have not been established. 1.2 Geriatrics Geriatrics (≥65 years of age): Elderly patients can use AA-IPRAVENT at the recommended dose. https://pdf.hres.ca/dpd_pm/00072339.PDF PM date: AUG 12, 1994 Source product: AA-IPRAVENT; DIN 02126222; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.